Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

More Press Releases

Stocks struggle higher as markets remain volatile; oil drops

Dec 10, 2018

NEW YORK — U.S. stocks remained volatile Monday as the market took a dive in early trading only to erase those losses later and end slightly higher. The Dow Jones Industrial Average lost as much as 507 points in early trading before ending with a gain of 34. Energy companies fell as the price of crude oil dropped 3 percent, giving back its gains from last week. Banks fell as investors expected slower increases in interest rates. Technology companies led the gainers. Qualcomm rose after the chipmaker said a Chinese court banned some Apple phones as part of a long-running...

Markets Right Now: US stocks end a bumpy day slightly higher

Dec 10, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Stocks ended another bumpy day slightly higher as gains by big technology companies helped the market erase an early plunge. Facebook added 3.2 percent and Microsoft rose 2.6 percent Monday. Chipmaker Qualcomm rose 2.2 percent after a Chinese court banned some Apple phones as part of a long-running dispute over patents. Energy companies fell as the price of crude oil dropped 3 percent, to give up its gains from last week. Exxon Mobil lost 1.4 percent. The S&P 500 rose 4 points, or 0.2 percent,...

Goodyear halts tire production in Venezuela as economy slips

Dec 10, 2018

VALENCIA, Venezuela — Goodyear Tire & Rubber Co. is halting production in Venezuela, making it the latest international corporation to abandon a South American nation in economic crisis, officials said Monday. Spokesman Eduardo Arguelles told The Associated Press that Goodyear-Venezuela had made the "difficult decision" to no longer produce tires in the country, which has seen an economic contraction worse than the U.S. Great Depression. "Our goal had been to maintain its operations, but economic conditions and U.S. sanctions have made this impossible," Arguelles said. The company had endured tens of millions in losses in recent years as the Venezuelan...

Markets Right Now: Stocks open sharply lower on Wall Street

Dec 10, 2018

NEW YORK — The latest on developments in financial markets (all times local): 9:35 a.m. Stocks are opening sharply lower as the arrest of a senior Chinese technology executive threatened to worsen trade tensions between China and the U.S. The price of oil also fell sharply early Thursday as OPEC leaders gathered to discuss possible cuts in production. The Dow Jones Industrial Average dropped as much as 500 points before erasing some of its losses. Boeing and Caterpillar, which would stand to lose much in an extended trade battle, fell the most in the Dow. Traders continued to shovel money...

Dow slides 700 points as US stocks veer sharply lower

Dec 10, 2018

U.S. stocks veered sharply lower in afternoon trading Tuesday, pulling the Dow Jones Industrial Average down 700 points. The wave of selling erased the market's gains from a day earlier, when stocks rallied on news that the U.S. and China had agreed to a temporary truce in their trade dispute. Investors' confidence in that truce appeared to falter Tuesday, contributing to renewed fears about a slowing global economy. Technology companies, banks and industrial stocks accounted for much of the sell-off as traders moved assets into the relative safety of U.S. government bonds, driving yields sharply lower. Utilities stocks rose. Smaller-company...

Subscribe to our newsletter!

Your Name

Your Email Address